Lyra Therapeutics to suspend trading on Nasdaq March 17 after delisting appeal withdrawal

Lyra Therapeutics, Inc.

Company withdrew appeal of February 2, 2026 Nasdaq delisting determination.
Nasdaq confirmed suspension of common stock trading at open on March 17, 2026.
Nasdaq will file Form 25 with SEC after internal procedural periods elapse.
No trading halt or additional compliance period cited; delisting is final.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.